[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial

2024-9-1

Rising costs of cancer medicines

2024-9-1

Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

2024-9-1

Improving individualised therapies in localised gastro-oesophageal adenocarcinoma

2024-9-1

Defining the quality of interdisciplinary care for patients with brain metastases: modified Delphi panel recommendations

2024-9-1

Enhancing cardiovascular disease risk management in childhood cancer survivors

2024-9-1

Correction to Lancet Oncol 2023; 24: 733–43

2024-9-1

Treatment of Richter transformation—immunotherapy to the rescue?

2024-9-1

Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial

2024-9-1

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

2024-9-1

The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group

2024-9-1

Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial

2024-9-1

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

2024-9-1

New immigration laws could undermine cancer research in the UK

2024-9-1

Poor progress on reducing alcohol consumption in Europe

2024-9-1

Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study

2024-9-1

European Commission approval for Dutch investment in radiopharmaceuticals

2024-9-1

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study

2024-9-1

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

2024-9-1

Contextualising legal and ethical conundrums of artificial intelligence in oncology

2024-9-1

Enhancing equity and long-term impact assessments in radiotherapy environmental studies

2024-9-1

Enhancing cardiovascular disease risk management in childhood cancer survivors

2024-9-1

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

2024-9-1

Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?

2024-9-1

New developments in tobacco control measures in Europe

2024-9-1

Petition to end travel insurance discrimination against people with cancer

2024-9-1

Multimodality imaging of a large incidental papillary fibroelastoma

2024-9-1

Enhancing equity and long-term impact assessments in radiotherapy environmental studies

2024-9-1

Radiation oncology: a call for papers for ESTRO 2025

2024-9-1

Legacies of conflict and humanitarian crises on cancer care

2024-8-27

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

2024-8-27

Translating the theranostic concept to neuro-oncology: disrupting barriers

2024-8-27

Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE

2024-8-1

A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care

2024-8-1

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

2024-8-1

Peru advances towards universal health care for patients with cancer

2024-8-1

Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial

2024-8-1

Disappointment facing patients with breast cancer as trastuzumab deruxtecan too expensive for NHS

2024-8-1

Ending financial discrimination for cancer survivors: embedding the Right to be Forgotten in legislation across Europe

2024-8-1

Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial

2024-8-1

Who does not benefit from whole-breast radiotherapy and how to find them?

2024-8-1

Imatinib in advanced GIST: if it's working, don’t stop a good thing

2024-8-1

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial

2024-8-1

The UK needs to be a leader, not a lagger, in the global cancer effort

2024-8-1

Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis

2024-8-1

Measuring success of adjuvant treatment for patients with melanoma

2024-8-1

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

2024-8-1

Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study

2024-8-1

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

2024-8-1

Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

2024-8-1